17/12/19 -"We have hiked our estimates on account of: 1. Faster than expected growth in the acquired Osiris business, which will result in a material uplift in the performance of the wound care business 2. ..."
Pages
64
Language
English
Published on
17/12/19
You may also be interested by these reports :
30/10/25
Amplifon’s Q3 results did not meet the company-compiled consensus. Sales growth was supported by strong performance in the Americas and a recovery in ...
29/10/25
We have broadly maintained our 2025 estimates, which remain in line with the 9M trading update and reconfirmed FY guidance. We have adopted a more ...
29/10/25
Emeis reported in-line Q3 revenue figures and reiterated its 2025 and mid-term objectives. This should be well received by the market, especially ...
28/10/25
Clariane reported 9M organic growth aligned with its maintained FY25 target, supported by strong price adjustments and buoyant volume increases. ...